{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:58:22Z","timestamp":1790423902622,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pcad.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:58:10Z","timestamp":1790146690000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Back to the future: Revisiting \u201cleave nothing behind\u201d when managing coronary artery disease"],"prefix":"10.1016","author":[{"given":"Filippo Luca","family":"Gurgoglione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Basavarajaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Wa\u0144ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Khialani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasim","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Malakouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.pcad.2026.09.008_bb0005","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2026.09.008_bb0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM198703193161201","article-title":"Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty","volume":"316","author":"Sigwart","year":"1987","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.pcad.2026.09.008_bb0015","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2026.09.008_bb0025","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","article-title":"Stent-related adverse events >1 year after percutaneous coronary intervention","volume":"75","author":"Madhavan","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4244\/AIJ-D-23-00010","article-title":"A 2024 scientific update on the clinical performance of drug-coated balloons","volume":"10","author":"Lazar","year":"2024","journal-title":"AsiaIntervention"},{"issue":"6","key":"10.1016\/j.pcad.2026.09.008_bb0035","first-page":"1069","article-title":"The evolution and revolution of drug coated balloons in coronary angioplasty: an up-to-date review of literature data","volume":"102","author":"Cortese","year":"2023","journal-title":"Catheter Cardiovasc Interv"},{"issue":"17","key":"10.1016\/j.pcad.2026.09.008_bb0040","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/eurheartj\/ehaf002","article-title":"Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study","volume":"46","author":"Fezzi","year":"2025","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.pcad.2026.09.008_bb0045","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/eurheartj\/ehag070","article-title":"Great debate: drug-coated balloons are preferable to drug-eluting stents for coronary in-stent restenosis","volume":"47","author":"Cortese","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2026.09.008_bb0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjcard.2025.08.012","article-title":"Sirolimus-coated balloon versus drug-eluting stent in elderly patients with coronary artery disease: a matched-based comparison","volume":"255","author":"Gurgoglione","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2026.09.008_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.carrev.2025.04.002","article-title":"Efficacy of drug-coated balloon angioplasty for coronary chronic total occlusion: a systematic review and meta-analysis","volume":"75","author":"Gurgoglione","year":"2025","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.pcad.2026.09.008_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjcard.2026.03.044","article-title":"Drug-coated balloon versus drug-eluting stent for coronary revascularization in patients with chronic kidney disease: a real-world propensity-matched study","volume":"268","author":"Gurgoglione","year":"2026","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-026-03110-6","article-title":"Nanocarrier SIroliMus-coated balloon-based percutaneous coronary intervention (PCI) versus drug-eluting stent (DES)-onLy PCI in patients with diabetes mellitus","volume":"25","author":"Gitto","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pcad.2026.09.008_bb0070","article-title":"Comparison of percutaneous intervention with drug coated balloons and drug eluting stents for de novo coronary artery disease: CIRCE, a systematic review and meta-analysis","author":"Wojciech","year":"2026","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.pcad.2026.09.008_bb0075","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/CIRCULATIONAHA.110.971606","article-title":"Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?","volume":"123","author":"Onuma","year":"2011","journal-title":"Circulation"},{"issue":"Suppl K","key":"10.1016\/j.pcad.2026.09.008_bb0080","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.4244\/EIJV7SKA9","article-title":"The PICCOLETO study and beyond","volume":"7","author":"Cortese","year":"2011","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcin.2016.10.027","article-title":"Very late scaffold thrombosis of bioresorbable vascular scaffold: systematic review and a meta-analysis","volume":"10","author":"Toyota","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"10.1016\/j.pcad.2026.09.008_bb0090","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jacc.2025.07.049","article-title":"Indications for use of drug-coated balloons in coronary intervention: academic research consortium position statement","volume":"86","author":"Fezzi","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2026.09.008_bb0095","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jacc.2022.05.017","article-title":"Coronary in-stent restenosis: JACC state-of-the-art review","volume":"80","author":"Giustino","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"10.1016\/j.pcad.2026.09.008_bb0100","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1093\/eurheartj\/eht241","article-title":"Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics","volume":"34","author":"Nakano","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0105","first-page":"558","article-title":"Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: results from a large single-center registry","volume":"96","author":"Plitt","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2020.10.018","article-title":"Incidence and predictors of target lesion failure in patients with lesions in small vessels undergoing PCI with contemporary drug-eluting stents: insights from the BIONICS study","volume":"25","author":"Danenberg","year":"2021","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.pcad.2026.09.008_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2023.05.021","article-title":"Relationship between stent length and very long-term target lesion failure following percutaneous coronary intervention for ST-elevation myocardial infarction in the drug-eluting stents era: insights from the EXAMINATION-EXTEND study","volume":"264","author":"Bujak","year":"2023","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.pcad.2026.09.008_bb0120","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4244\/EIJ-D-19-00296","article-title":"Clinical outcomes of long stenting in the drug-eluting stent era: patient-level pooled analysis from the GRAND-DES registry","volume":"16","author":"Kong","year":"2021","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.pcad.2026.09.008_bb0125","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.4244\/EIJ-D-21-00636","article-title":"Coronary vasomotion after treatment with drug-coated balloons or drug-eluting stents: a prospective, open-label, single-centre randomised trial","volume":"18","author":"Kawai","year":"2022","journal-title":"EuroIntervention"},{"issue":"9","key":"10.1016\/j.pcad.2026.09.008_bb0130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4244\/EIJ-D-23-00849","article-title":"Predictors of late lumen enlargement after drug-coated balloon angioplasty for de novo coronary lesions","volume":"20","author":"Yamamoto","year":"2024","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2026.09.008_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2026.107361","article-title":"Antiplatelet treatment after drug-coated balloon treatment: review of the current evidence and future perspectives","volume":"296","author":"Cortese","year":"2026","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.pcad.2026.09.008_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028413","article-title":"Single-antiplatelet treatment after coronary angioplasty with drug-coated balloon","volume":"12","author":"Cortese","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.pcad.2026.09.008_bb0145","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jcin.2018.02.002","article-title":"Impact of optimized procedure-related factors in drug-eluting balloon angioplasty for treatment of in-stent restenosis","volume":"11","author":"Rhee","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0150","first-page":"730","article-title":"Prognostic significance of bailout stenting for residual stenosis or dissection following drug-coated balloon angioplasty: a sub-analysis of the EASTBOURNE study","volume":"106","author":"Gurgoglione","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.pcad.2026.09.008_bb0155","first-page":"1656","article-title":"Enhanced drug effect with cutting balloon followed by drug coated balloon in a rabbit model","volume":"105","author":"Shiozaki","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1007\/s12928-026-01330-x","article-title":"Cutting vs standard balloon for lesion preparation in drug-coated balloon-only PCI: the NATURE randomised trial","author":"Asano","year":"2026","journal-title":"Cardiovasc Interv Ther"},{"issue":"9","key":"10.1016\/j.pcad.2026.09.008_bb0165","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.4244\/EIJ-D-25-01066","article-title":"Intracoronary imaging guidance for de novo coronary lesion treatment with drug-coated balloons","volume":"22","author":"Amabile","year":"2026","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2026.09.008_bb0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.carrev.2021.03.012","article-title":"Impact of optimal preparation before drug-coated balloon dilatation for de novo lesion in patients with coronary artery disease","volume":"35","author":"Konishi","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"issue":"13","key":"10.1016\/j.pcad.2026.09.008_bb0175","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcin.2024.04.014","article-title":"Intravascular ultrasound vs angiography-guided drug-coated balloon angioplasty: the ULTIMATE III trial","volume":"17","author":"Gao","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0180","article-title":"Physiology-guided drug-coated balloon angioplasty: what we know and what is yet to be understood","author":"Frazzetto","year":"2026","journal-title":"Catheter Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.pcad.2026.09.008_bb0185","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10554-019-01649-y","article-title":"Comparison of fractional flow reserve and angiographic characteristics after balloon angioplasty in de novo coronary lesions","volume":"35","author":"Chung","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.pcad.2026.09.008_bb0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10554-019-01707-5","article-title":"Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions","volume":"36","author":"Chung","year":"2020","journal-title":"Int J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4244\/AIJ-D-25-00057","article-title":"Angiographic and functional assessment after paclitaxel or sirolimus drug-coated balloons for de novo coronary artery disease in small vessels: PICCOLETO VI study","volume":"12","author":"Fezzi","year":"2026","journal-title":"AsiaIntervention"},{"key":"10.1016\/j.pcad.2026.09.008_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacasi.2026.06.043","article-title":"Physiological patterns of coronary artery disease and drug-coated balloon performance","author":"Fezzi","year":"2026","journal-title":"JACC Asia"},{"issue":"8","key":"10.1016\/j.pcad.2026.09.008_bb0205","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcin.2015.04.008","article-title":"3-year follow-up of the balloon elution and late loss optimization study (BELLO)","volume":"8","author":"Latib","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"10261","key":"10.1016\/j.pcad.2026.09.008_bb0210","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0140-6736(20)32173-5","article-title":"Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial","volume":"396","author":"Jeger","year":"2020","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2026.09.008_bb0215","first-page":"587","article-title":"Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: the RESTORE small vessel disease China trial","volume":"95","author":"Tian","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"issue":"24","key":"10.1016\/j.pcad.2026.09.008_bb0220","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.jcin.2020.08.035","article-title":"Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial","volume":"13","author":"Cortese","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.pcad.2026.09.008_bb0225","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jcin.2023.02.011","article-title":"Long-term outcome of drug-coated balloon vs drug-eluting stent for small coronary vessels: PICCOLETO-II 3-year follow-up","volume":"16","author":"Cortese","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.pcad.2026.09.008_bb0230","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCULATIONAHA.119.039797","article-title":"Guiding principles for chronic total occlusion percutaneous coronary intervention","volume":"140","author":"Brilakis","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0235","first-page":"11","article-title":"Histopathology of coronary artery chronic total occlusions and its relevance to percutaneous recanalization techniques","volume":"15","author":"Sawan","year":"2026","journal-title":"Interv Cardiol Clin"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0240","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-23-00490","article-title":"Contemporary outcomes of chronic total occlusion percutaneous coronary intervention in Europe: the ERCTO registry","volume":"20","author":"Vadal\u00e0","year":"2024","journal-title":"EuroIntervention"},{"issue":"7","key":"10.1016\/j.pcad.2026.09.008_bb0245","first-page":"3783","article-title":"Drug-coated balloons in chronic total occlusion percutaneous coronary intervention: insights from the PROGRESS-CTO registry","volume":"106","author":"Mutlu","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"issue":"18","key":"10.1016\/j.pcad.2026.09.008_bb0250","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.jcin.2025.07.036","article-title":"Drug-coated balloons in the European registry of chronic total occlusion: the ERCTO registry","volume":"18","author":"Ciardetti","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"14","key":"10.1016\/j.pcad.2026.09.008_bb0255","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.jcin.2026.05.009","article-title":"Drug-coated balloon-based angioplasty for chronic total occlusions: the PICCOLETO X study","volume":"19","author":"Cortese","year":"2026","journal-title":"JACC Cardiovasc Interv"},{"issue":"21","key":"10.1016\/j.pcad.2026.09.008_bb0260","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.3390\/jcm14217576","article-title":"Blended coronary revascularization with drug-coated balloon and drug-eluting stent: a narrative review on rationale, clinical evidence, and future perspectives","volume":"14","author":"Gurgoglione","year":"2025","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.pcad.2026.09.008_bb0265","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jcin.2013.07.005","article-title":"The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease","volume":"6","author":"Costopoulos","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"10.1016\/j.pcad.2026.09.008_bb0270","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.123.013232","article-title":"Drug-coated balloon angioplasty for de novo lesions on the left anterior descending artery","volume":"16","author":"Gitto","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.pcad.2026.09.008_bb0275","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.recesp.2025.07.004","article-title":"Drug-coated balloon-based versus drug-eluting stent-only treatment for single de novo diffuse coronary lesions","volume":"79","author":"Shin","year":"2026","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0280","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jcin.2022.09.054","article-title":"Drug-coated balloon angioplasty guided by postpercutaneous coronary intervention pressure gradient: the REDUCE-STENT retrospective registry","volume":"16","author":"Leone","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.pcad.2026.09.008_bb0285","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.4244\/EIJ-D-23-00502","article-title":"Immediate and follow-up outcomes of drug-coated balloon angioplasty in de novo long lesions on large coronary arteries","volume":"19","author":"Leone","year":"2023","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0290","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12933-022-01637-y","article-title":"Microvascular complications identify a specific coronary atherosclerotic phenotype in patients with type 2 diabetes mellitus","volume":"21","author":"Montone","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.pcad.2026.09.008_bb0295","doi-asserted-by":"crossref","DOI":"10.31083\/RCM47550","article-title":"The extent and phenotype of coronary artery disease in diabetes and prediabetes: insights from imaging studies and potential therapeutic implications","volume":"27","author":"Gurgoglione","year":"2026","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0300","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12933-025-02922-2","article-title":"Drug-coated balloons and diabetes: a review","volume":"24","author":"Frazzetto","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.pcad.2026.09.008_bb0305","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.4244\/EIJ-D-21-01065","article-title":"Percutaneous coronary intervention of bifurcation lesions","volume":"18","author":"Hildick-Smith","year":"2022","journal-title":"Eurointervention"},{"issue":"16","key":"10.1016\/j.pcad.2026.09.008_bb0310","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4244\/EIJ-D-20-00169","article-title":"Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European bifurcation club","volume":"16","author":"Burzotta","year":"2021","journal-title":"Eurointervention"},{"issue":"9","key":"10.1016\/j.pcad.2026.09.008_bb0315","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1253\/circj.CJ-15-0264","article-title":"Long-term clinical outcomes of true and non-true bifurcation lesions according to Medina classification- results from the COBIS (COronary BIfurcation Stent) II registry","volume":"79","author":"Park","year":"2015","journal-title":"Circ J"},{"issue":"20","key":"10.1016\/j.pcad.2026.09.008_bb0320","doi-asserted-by":"crossref","first-page":"e1177","DOI":"10.4244\/EIJ-D-25-00201","article-title":"Drug-coated balloons for coronary bifurcation lesions","volume":"21","author":"Fezzi","year":"2025","journal-title":"EuroIntervention"},{"issue":"8","key":"10.1016\/j.pcad.2026.09.008_bb0325","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4244\/EIJV11I8A177","article-title":"DANUBIO - a new drug-eluting balloon for the treatment of side branches in bifurcation lesions: six-month angiographic follow-up results of the DEBSIDE trial","volume":"11","author":"Berland","year":"2015","journal-title":"Eurointervention"},{"key":"10.1016\/j.pcad.2026.09.008_bb0330","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijcard.2015.04.002","article-title":"Six month angiographic result of supplementary paclitaxel-eluting balloon deployment to treat side branch ostium narrowing (SARPEDON)","volume":"187","author":"Jim","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2026.09.008_bb0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.carrev.2023.04.010","article-title":"Safety and efficacy of a hybrid approach combining a paclitaxel-coated balloon with a new generation drug-eluting stent in patients with de novo true coronary bifurcation lesions","volume":"54","author":"Kasbaoui","year":"2023","journal-title":"Cardiovasc Revasc Med"},{"issue":"7","key":"10.1016\/j.pcad.2026.09.008_bb0340","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00392-015-0957-6","article-title":"Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial","volume":"105","author":"Kleber","year":"2016","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2026.09.008_bb0345","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CM9.0000000000000743","article-title":"A drug-eluting balloon for the treatment of coronary bifurcation lesions in the side branch: a prospective multicenter randomized (BEYOND) clinical trial in China","volume":"133","author":"Jing","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2024.08.067","article-title":"Drug-coated balloon angioplasty of the side branch during provisional stenting: the multicenter randomized DCB-BIF trial","volume":"85","author":"Gao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2026.09.008_bb0355","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.carrev.2024.07.021","article-title":"Angiographic and clinical impact of balloon inflation time in percutaneous coronary interventions with sirolimus-coated balloon: a subanalysis of the EASTBOURNE study","volume":"73","author":"Gurgoglione","year":"2025","journal-title":"Cardiovasc Revasc Med"},{"issue":"8","key":"10.1016\/j.pcad.2026.09.008_bb0360","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jcin.2026.02.009","article-title":"Drug-coated balloon angioplasty vs drug-eluting stents in noncomplex coronary bifurcation lesions: the REC-CAGEFREE I trial","volume":"19","author":"Zhu","year":"2026","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0365","series-title":"Coronary Bifurcation Lesions Side Branch Optimal Treatment Study: The BILBO Multicentre Study","author":"Cortese","year":"2026"},{"issue":"10457","key":"10.1016\/j.pcad.2026.09.008_bb0370","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0140-6736(24)01594-0","article-title":"Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial","volume":"404","author":"Gao","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0375","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jacc.2025.10.027","article-title":"Drug-coated balloon angioplasty vs up-front stenting for de novo CAD: 3-year follow-up of REC-CAGEFREE I trial","volume":"87","author":"Tao","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2026.09.008_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2026.134267","article-title":"Drug-coated balloon versus drug-eluting stent for treating de novo proximal left anterior descending artery lesions: insights from the REC-CAGEFREE I trial","volume":"451","author":"Cheng","year":"2026","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0385","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCULATIONAHA.126.079033","article-title":"Sirolimus-eluting balloon with provisional stenting versus systematic drug-eluting stent implantation to treat de novo coronary lesions: a randomized, open-label, noninferiority trial","volume":"154","author":"Spaulding","year":"2026","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pcad.2026.09.008_bb0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0395","first-page":"e4","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pcad.2026.09.008_bb0400","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jama.2024.1361","article-title":"Paclitaxel-coated balloon vs uncoated balloon for coronary in-stent restenosis: the AGENT IDE randomized clinical trial","volume":"331","author":"Yeh","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pcad.2026.09.008_bb0405","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jcin.2013.08.011","article-title":"A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial","volume":"7","author":"Xu","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"10.1016\/j.pcad.2026.09.008_bb0410","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/eurheartj\/ehad026","article-title":"Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial","volume":"44","author":"Giacoppo","year":"2023","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.pcad.2026.09.008_bb0415","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jacc.2013.12.006","volume":"63","author":"Alfonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2026.09.008_bb0420","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jcin.2018.02.037","article-title":"3-year clinical follow-up of the RIBS IV clinical trial: a prospective randomized study of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis in coronary arteries previously treated with drug-eluting stents","volume":"11","author":"Alfonso","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"38","key":"10.1016\/j.pcad.2026.09.008_bb0425","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1093\/eurheartj\/ehz594","article-title":"Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)","volume":"41","author":"Giacoppo","year":"2020","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.pcad.2026.09.008_bb0430","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2026.09.008_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2026.03.021","article-title":"Sirolimus-eluting balloon vs repeat drug-eluting stent or balloon angioplasty for coronary in-stent restenosis","author":"Cutlip","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0440","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4244\/EIJ-E-23-00015","article-title":"Bioresorbable coronary scaffolds are ready for a comeback: pros and cons","volume":"19","author":"Stone","year":"2023","journal-title":"EuroIntervention"},{"issue":"9576","key":"10.1016\/j.pcad.2026.09.008_bb0445","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(07)60853-8","article-title":"Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial","volume":"369","author":"Erbel","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0450","first-page":"E1","article-title":"BIOSOLVE-IV-registry: safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients","volume":"98","author":"Verheye","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0455","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijcard.2015.07.002","article-title":"Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: results from a multicenter Italian experience","volume":"199","author":"Moscarella","year":"2015","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2026.09.008_bb0460","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003148","article-title":"Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: a multicenter Italian experience","volume":"9","author":"Moscarella","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.pcad.2026.09.008_bb0465","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjcard.2015.05.049","article-title":"Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions","volume":"116","author":"Cortese","year":"2015","journal-title":"Am J Cardiol"},{"issue":"10059","key":"10.1016\/j.pcad.2026.09.008_bb0470","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial","volume":"388","author":"Serruys","year":"2016","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.pcad.2026.09.008_bb0475","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","article-title":"3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial","volume":"70","author":"Kereiakes","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10157","key":"10.1016\/j.pcad.2026.09.008_bb0480","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","article-title":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial","volume":"392","author":"Stone","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pcad.2026.09.008_bb0485","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jacc.2023.05.003","article-title":"5-year outcomes after bioresorbable coronary scaffolds implanted with improved technique","volume":"82","author":"Stone","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2024.08.050","article-title":"Early and late outcomes with the absorb bioresorbable vascular scaffold: final report from the ABSORB clinical trial program","volume":"18","author":"Power","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.pcad.2026.09.008_bb0495","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","article-title":"Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials","volume":"137","author":"Ali","year":"2018","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.pcad.2026.09.008_bb0500","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.jacc.2018.02.051","article-title":"Neoatherosclerosis 5 years after bioresorbable vascular scaffold implantation","volume":"71","author":"Moriyama","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.pcad.2026.09.008_bb0505","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jacc.2017.09.014","article-title":"Mechanisms of very late bioresorbable scaffold thrombosis: the INVEST registry","volume":"70","author":"Yamaji","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0510","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13063-022-07028-8","article-title":"The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial","volume":"24","author":"Wu","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.pcad.2026.09.008_bb0515","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2017.12.053","article-title":"In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: insights from the BIOSOLVE-II first-in-man trial","volume":"255","author":"Garcia-Garcia","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0520","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.124.014665","article-title":"Optimal predilatation treatment before implantation of a Magmaris bioresorbable scaffold in coronary artery stenosis: the OPTIMIS trial","volume":"18","author":"Hansen","year":"2025","journal-title":"Circ Cardiovasc Interv"},{"issue":"16","key":"10.1016\/j.pcad.2026.09.008_bb0525","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.jacc.2025.12.024","article-title":"Sirolimus-eluting iron bioresorbable scaffolds vs everolimus-eluting stents for percutaneous coronary intervention: a randomized trial (IRONMAN II)","volume":"87","author":"Gao","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0530","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12916-025-04254-0","article-title":"Firesorb bioresorbable scaffold for de novo coronary artery disease: 1-year clinical outcomes","volume":"23","author":"Jiang","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.pcad.2026.09.008_bb0535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.carrev.2025.02.001","article-title":"Clinical safety and performance of the third-generation Fantom Encore sirolimus-eluting bioresorbable scaffold: insights from a single-center study","volume":"82","author":"Amata","year":"2026","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.pcad.2026.09.008_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102304","volume":"65","author":"Saito","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.pcad.2026.09.008_bb0545","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jcin.2025.01.426","article-title":"Percutaneous coronary treatment with bioadaptor implant vs drug-eluting stent: 2-year outcomes from BIOADAPTOR RCT","volume":"18","author":"Saito","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"10464","key":"10.1016\/j.pcad.2026.09.008_bb0550","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(24)02227-X","article-title":"Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART)","volume":"404","author":"Erlinge","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pcad.2026.09.008_bb0555","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4244\/EIJY15M10_01","article-title":"In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system","volume":"12","author":"Granada","year":"2016","journal-title":"EuroIntervention"},{"issue":"20","key":"10.1016\/j.pcad.2026.09.008_bb0560","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.jcin.2017.06.021","article-title":"The SABRE trial (sirolimus angioplasty balloon for coronary in-stent restenosis): angiographic results and 1-year clinical outcomes","volume":"10","author":"Verheye","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.pcad.2026.09.008_bb0565","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ejvs.2018.11.019","article-title":"An experimental study of paclitaxel embolisation during drug coated balloon angioplasty","volume":"57","author":"Boitet","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"6","key":"10.1016\/j.pcad.2026.09.008_bb0570","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1177\/15266028231161215","article-title":"Differences in biologic drug effects and distal particulate embolization in three paclitaxel-coated balloons for femoropopliteal lesions in a rabbit model","volume":"31","author":"Yoshikawa","year":"2024","journal-title":"J Endovasc Ther"},{"issue":"6","key":"10.1016\/j.pcad.2026.09.008_bb0575","first-page":"1434","article-title":"Vascular response, downstream effect, and pharmacokinetics after sirolimus- and paclitaxel-coated balloons in porcine coronary arteries","volume":"105","author":"Kawai","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0580","series-title":"Changes in Microvascular Resistance Following Angioplasty with Crystalline Versus Amorphous DCB for De Novo Lesions: The PICCOLETO VI Mi-Re Study","author":"Cortese","year":"2026"},{"issue":"7","key":"10.1016\/j.pcad.2026.09.008_bb0585","first-page":"1238","article-title":"How to perform a successful drug-coated balloon angioplasty? Tips and tricks","volume":"102","author":"Basavarajaiah","year":"2023","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0590","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amjcard.2024.12.015","article-title":"Predictors and long-term prognostic significance of bailout stenting during percutaneous coronary interventions with sirolimus-coated balloon: a subanalysis of the Eastbourne study","volume":"239","author":"Gurgoglione","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2026.09.008_bb0595","article-title":"Lesion preparation before drug-coated balloon angioplasty for in-stent restenosis: comparison between specialty and conventional balloons","author":"Khialani","year":"2026","journal-title":"REC Interv Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.09.008_bb0600","first-page":"625","article-title":"Comparison of sirolimus-versus paclitaxel-coated balloons in coronary artery disease: one-year results of two real-world prospective registries","volume":"106","author":"Vlieger","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.09.008_bb0605","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.amjcard.2026.04.056","article-title":"Paclitaxel versus sirolimus-coated balloons for coronary artery disease: 2-year follow-up of 2 large registries","volume":"271","author":"Gurgoglione","year":"2026","journal-title":"Am J Cardiol"},{"issue":"23","key":"10.1016\/j.pcad.2026.09.008_bb0610","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.jcin.2023.09.026","article-title":"A prospective randomized trial comparing sirolimus-coated balloon with paclitaxel-coated balloon in de novo small vessels","volume":"16","author":"Ninomiya","year":"2023","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:12:56Z","timestamp":1790421176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062026001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":122,"alternative-id":["S0033062026001076"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2026.09.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Back to the future: Revisiting \u201cleave nothing behind\u201d when managing coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}